Home Ingredients Tonalin® CLA (Conjugated Linoleic Acid)
Weight ManagementMetabolic HealthMuscle & Recovery

Tonalin® CLA (Conjugated Linoleic Acid)

Evidence Level
Moderate
3 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

Tonalin® (ADM / BASF) is the most-studied branded conjugated linoleic acid (CLA) preparation — an ~80% isomer mixture of c9,t11 and t10,c12 conjugated linoleic acid produced from non-GMO safflower oil. The c9,t11 and t10,c12 isomers have distinct biological actions: the t10,c12 form is associated with reductions in body fat mass while c9,t11 is associated with metabolic effects. Long-term human trials with Tonalin® CLA show modest reductions in body fat mass in overweight adults, although meta-analyses indicate effect sizes are small and there are documented cardiometabolic safety signals — including HDL cholesterol decreases and signals of insulin resistance and oxidative stress in some trials — that should be weighed when considering long-term use.

Studied Dose Typical Tonalin® CLA dose in body composition trials: 3.2–6.4 g/day total CLA isomers, usually split with meals, for 6–24 months. Most efficacy data centers on 3.4 g/day for at least 6 months.
Active Compound ~80% conjugated linoleic acid (~50:50 mix of c9,t11 and t10,c12 isomers) — Tonalin® CLA by ADM / BASF; produced from non-GMO safflower oil

Benefits

Modest reduction in body fat mass

Long-term Tonalin® CLA supplementation has been associated with statistically significant but modest reductions in body fat mass in overweight and obese adults. Meta-analyses estimate roughly 0.05–0.1 kg of fat loss per week beyond placebo, with effects accumulating over months and being more reliable than weight loss alone.

Supported by Trial 2, Trial 1

Regional changes in abdominal fat

Six-month trials with Tonalin®-grade CLA have reported regional reductions in abdominal fat alongside total fat changes in overweight adults, suggesting that CLA may modestly shift fat distribution as well as total fat mass over multi-month timeframes.

Supported by Trial 1, Trial 2

Support for lean body mass during weight loss

Some clinical trials have observed preservation or slight increases in lean body mass during weight loss with CLA supplementation, with the t10,c12 isomer being the leading candidate for this effect. Lean mass preservation is relevant to maintaining metabolic rate during energy restriction.

Supported by Trial 2, Trial 1

Complementary to resistance training

Combined CLA supplementation and resistance training has been studied in adults with results suggesting modest additive effects on body composition outcomes versus training alone. CLA is best regarded as a small adjunct to diet and exercise, not a standalone fat-loss agent.

Supported by Trial 2, Trial 1

Mechanism of action

1

Isomer-specific actions on adipocyte metabolism

The t10,c12 isomer in Tonalin® reduces lipoprotein lipase activity, decreases triglyceride uptake into adipocytes, and increases fatty acid oxidation in skeletal muscle. The c9,t11 isomer has different signaling — these distinct actions explain the differential body composition and metabolic effects of CLA mixtures.

2

PPAR pathway modulation

CLA isomers act as ligands for peroxisome proliferator-activated receptors (PPARα and PPARγ), influencing transcription of genes involved in fatty acid oxidation, adipocyte differentiation, and inflammatory tone. PPAR signalling underlies many of CLA's reported metabolic and immune effects.

3

Reduced adipocyte size and lipid storage

Animal and cell models show CLA isomers reduce adipocyte size by limiting triglyceride accumulation and promoting apoptosis of mature adipocytes. Long-term human supplementation appears to produce smaller, slower analogues of these changes, contributing to gradual reductions in fat mass.

4

Mixed effects on insulin signalling and lipoprotein metabolism

The t10,c12 isomer has been associated with reductions in adipose insulin sensitivity, decreases in HDL cholesterol, and signals of oxidative stress and elevated CRP in some long-term trials. These off-target effects appear to be isomer-specific and warrant honest framing when discussing CLA's safety profile.

Clinical trials

1
CLA for Regional Fat Mass in Overweight Adults — 6-Month Trial

Randomized, double-blind, placebo-controlled trial of CLA supplementation (~3.4 g/day) versus placebo in 118 overweight and obese adults over 6 months. Outcomes: total and regional body fat, lean body mass measured by DXA. Published in Journal of Nutrition.

118 overweight or obese adults; 6-month intervention.

CLA produced significant regional-specific decreases in body fat mass versus placebo, with effects more pronounced in some anatomical regions than others. Lean mass was largely preserved. Effect sizes were modest but clinically observable across the 6-month window.

2
CLA Meta-Analysis on Fat Mass Reduction

Meta-analysis of randomized controlled trials of CLA supplementation in humans, evaluating effects on body fat mass. Published in American Journal of Clinical Nutrition.

Pooled trial population across multiple CLA dose-response studies.

CLA supplementation produced statistically significant reductions in fat mass versus placebo, with an estimated effect of roughly 0.05–0.09 kg per week and a relatively consistent direction across studies. Effect sizes are modest and emphasized as small compared with diet and exercise.

3
Long-Term CLA Body Composition Systematic Review

Systematic review and meta-analysis of long-term CLA supplementation in overweight and obese individuals. Published in European Journal of Nutrition.

Pooled trials of overweight and obese adults; long-term CLA use.

The systematic review concluded that long-term CLA supplementation produces statistically significant but clinically modest changes in body composition, and the evidence does not strongly support CLA as a meaningful weight-management intervention on its own. Several included trials documented safety signals.

Side effects and drug interactions

Common Potential side effects

GI upset, soft stools, or dyspepsia particularly at higher doses (>4 g/day).
Some long-term trials report HDL cholesterol decreases — a cardiovascular safety signal.
Signals of reduced insulin sensitivity and elevated oxidative stress (CRP) with certain CLA isomers.
Possible mild liver enzyme elevations in a subset of long-term users; monitor with prolonged use.
Long-term safety in specific high-risk groups (advanced metabolic syndrome, diabetes) remains incompletely characterized.

Important Drug interactions

Statins and other lipid-modifying drugs — potential interaction via HDL changes; coordinate monitoring.
Insulin and oral antidiabetics — monitor glucose carefully given CLA's reported insulin sensitivity effects.
Warfarin and antiplatelets — CLA may modestly influence platelet function; coordinate INR monitoring.
Hepatically metabolized drugs — discuss with clinician given possible liver enzyme effects.

More Weight Management Ingredients

Antioxidant
Green Tea
Green tea extract, derived from Camellia sinensis leaves, is rich in antioxidants like cat…
Metabolic Health
Berberine
Berberine is a bioactive compound extracted from plants like barberry and goldenseal, know…
Metabolic Health
Inositol (Myo-Inositol)
Inositol is a naturally occurring sugar alcohol that acts as a secondary messenger in insu…
Weight Management
Capsaicin / Capsicum Extract (Cayenne Pepper)
Capsicum extract (cayenne pepper, red chili pepper) and its primary bioactive capsaicin ar…

Explore Other Ingredients

Athletic Performance
Cordyceps
Cordyceps is a medicinal fungus traditionally used in Tibetan and Chinese medicine for ene…
Cardiovascular
CoEnzyme Q10
Coenzyme Q10 (CoQ10) is a lipid-soluble compound essential to mitochondrial ATP production…
Weight Management
CaloriBurn GP® (Grains of Paradise)
CaloriBurn GP® is NNB Nutrition's premium grains of paradise extract standardized for all…

Frequently asked questions about Tonalin® CLA (Conjugated Linoleic Acid)

What is the recommended dosage of Tonalin® CLA (Conjugated Linoleic Acid)?

The clinically studied dose for Tonalin® CLA (Conjugated Linoleic Acid) is Typical Tonalin® CLA dose in body composition trials: 3.2–6.4 g/day total CLA isomers, usually split with meals, for 6–24 months. Most efficacy data centers on 3.4 g/day for at least 6 months.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Tonalin® CLA (Conjugated Linoleic Acid) used for?

Tonalin® CLA (Conjugated Linoleic Acid) is studied for modest reduction in body fat mass, regional changes in abdominal fat, support for lean body mass during weight loss. Long-term Tonalin® CLA supplementation has been associated with statistically significant but modest reductions in body fat mass in overweight and obese adults. Meta-analyses estimate roughly 0.05–0.

Are there side effects from taking Tonalin® CLA (Conjugated Linoleic Acid)?

Reported potential side effects may include: GI upset, soft stools, or dyspepsia particularly at higher doses (>4 g/day). Some long-term trials report HDL cholesterol decreases — a cardiovascular safety signal. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Tonalin® CLA (Conjugated Linoleic Acid) interact with medications?

Known drug interactions may include: Statins and other lipid-modifying drugs — potential interaction via HDL changes; coordinate monitoring. Insulin and oral antidiabetics — monitor glucose carefully given CLA's reported insulin sensitivity effects. Consult a pharmacist or healthcare provider if you take prescription medications.

Is Tonalin® CLA (Conjugated Linoleic Acid) good for weight management?

Yes, Tonalin® CLA (Conjugated Linoleic Acid) is researched for Weight Management support. Long-term Tonalin® CLA supplementation has been associated with statistically significant but modest reductions in body fat mass in overweight and obese adults. Meta-analyses estimate roughly 0.05–0.

References(5 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Gaullier JM, Halse J, Høivik HO, Høye K, Syvertsen C, Nurminiemi M, Hassfeld C, Einerhand A, O'Shea M, Gudmundsen O. Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese. Br J Nutr. 2007;97(3):550-60. doi: 10.1017/S0007114507381324.PubMedUsed to support: 6-month RCT in 118 overweight/obese adults — CLA supplementation produced regional-specific decreases in body fat mass vs placebo with lean mass preservation, supporting CLA's modest but measurable body composition effects.
  2. Gaullier JM, Halse J, Høye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. J Nutr. 2005;135(4):778-84. doi: 10.1093/jn/135.4.778.PubMedUsed to support: 24-month extension trial — long-term Tonalin®-style CLA (3.4 g/day) reduced body fat mass and was generally well tolerated in healthy overweight adults, supporting durability of effect at modest magnitude.
  3. Whigham LD, Watras AC, Schoeller DA. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Am J Clin Nutr. 2007;85(5):1203-11. doi: 10.1093/ajcn/85.5.1203.PubMedUsed to support: Meta-analysis — CLA at typical doses (~3.4 g/day) reduces fat mass by roughly 0.05–0.09 kg/week vs placebo; effect is statistically robust but modest in magnitude compared with diet and exercise.
  4. Onakpoya IJ, Posadzki PP, Watson LK, Davies LA, Ernst E. The efficacy of long-term conjugated linoleic acid (CLA) supplementation on body composition in overweight and obese individuals: a systematic review and meta-analysis of randomized clinical trials. Eur J Nutr. 2012;51(2):127-34. doi: 10.1007/s00394-011-0253-9.PubMedUsed to support: Systematic review and meta-analysis — long-term CLA supplementation produces statistically significant but clinically modest body composition changes; evidence does not convincingly support clinically meaningful effects on its own.
  5. Risérus U, Basu S, Jovinge S, Fredrikson GN, Arnlöv J, Vessby B. Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance. Circulation. 2002;106(15):1925-9. doi: 10.1161/01.CIR.0000033589.15413.48.PubMedUsed to support: Trial — supplementation with the t10,c12 CLA isomer induced oxidative stress, elevated CRP, and was associated with reduced insulin sensitivity in obese men; a foundational safety signal underpinning the cardiometabolic caution around long-term CLA use.